Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06588348 · ClinicalTrials.gov registry record · Early Phase 1
Corticosteroid Effect on Achalasia Variant EGJOO
A Early Phase 1 study of Esophagogastric Junction Outflow Obstruction, sponsored by Baylor Research Institute.
- Active
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06588348: Active Early Phase 1 study of Esophagogastric Junction Outflow Obstruction, sponsored by Baylor Research Institute.
NCT06588348 is a Early Phase 1 study of Esophagogastric Junction Outflow Obstruction that is active but no longer recruiting, run by Baylor Research Institute. The registered enrollment target is 12 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06588348, a Early Phase 1 study of Esophagogastric Junction Outflow Obstruction, is active but no longer recruiting, sponsored by Baylor Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
EGJOO is a disorder in which the muscles of the esophagus (swallowing tube) do not function in a coordinated fashion so that swallowed material does not pass easily into the stomach. EGJOO often causes symptoms of swallowing difficulties and chest pain. The cause of EGJOO and its optimal treatment are not clear. The investigators research team suspects that EGJOO might be caused by an allergy that involves the esophagus, and that treatment with medications called corticosteroids might improve function of the esophageal muscles. The purpose of this study is to learn how corticosteroid therapy affects the muscles of the esophagus in patients suffering with EGJOO.
Primary Outcome
Median integrated relaxation pressure (IRP) of the lower esophageal sphincter (LES) obtained through esophageal manometry procedure
Conditions Studied
Interventions
- OTHER Survey
- DRUG Steroid treatment
- PROCEDURE Esophageal Manometry
Study Locations (1)
Texas
- Baylor University Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-07-26 |
| Est. Completion | 2026-11 |
| Phase | Early Phase 1 |
What the registry record for NCT06588348 still lists
NCT06588348 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Esophagogastric Junction Outflow Obstruction appearing as the primary indexed condition, and to 3 interventions - of which Survey is the first listed.
NCT06588348 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06588348 about?
NCT06588348 is a clinical study titled "Corticosteroid Effect on Achalasia Variant EGJOO". EGJOO is a disorder in which the muscles of the esophagus (swallowing tube) do not function in a coordinated fashion so that swallowed material does not pass easily into the stomach. EGJOO often causes symptoms of swallowing difficulties and chest pain. The cause of EGJOO and its optimal treatment a...
What is the current status of trial NCT06588348?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2022-07-26. Estimated completion is 2026-11.
What conditions does trial NCT06588348 study?
This clinical trial studies the following conditions: Esophagogastric Junction Outflow Obstruction.
What interventions are being tested in trial NCT06588348?
The interventions under investigation include: Survey (OTHER), Steroid treatment (DRUG), Esophageal Manometry (PROCEDURE).
Who is sponsoring clinical trial NCT06588348?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06588348 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06588348's enrollment target sits among peer trials
12 1530th of 2000 higher than 401 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI